- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05248555
Det nasjonale australske HCV Point-of-Care-testprogrammet – minimalt datasett
Det nasjonale australske HCV Point-of-Care-testingprogrammet: En observasjonskohortstudie for å evaluere bruken av Finger-stick Point-of-care Hepatitt C-testing for å forbedre diagnose og behandling av HCV-infeksjon - Minimalt datasett
The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4
Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6
The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.
The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.
An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Simon Comben, BSc, MN
- Telefonnummer: +6193480777
- E-post: scomben@kirby.unsw.edu.au
Studer Kontakt Backup
- Navn: David Silk, BSc
- Telefonnummer: +61293850900
- E-post: dsilk@kirby.unsw.edu.au
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australia
- Aktiv, ikke rekrutterende
- Justice Health and Forensic Mental Health Network
-
-
Queensland
-
Aldershot, Queensland, Australia, 4650
- Rekruttering
- Maryborough Correctional Centre
-
Ta kontakt med:
- Ashley Willman
- Telefonnummer: (07) 4123 7600
- E-post: ashley.willmann@health.qld.gov.au
-
Brisbane, Queensland, Australia, 4000
- Rekruttering
- QuIHN
-
Ta kontakt med:
- Nicholas Alexander
- Telefonnummer: 3620 8111
- E-post: nalexander@quihn.org
-
Cairns, Queensland, Australia
- Rekruttering
- Lotus Glen Correctional Centre
-
Ta kontakt med:
- Darren Russell
-
Hovedetterforsker:
- Darren Russell
-
Coorparoo, Queensland, Australia, 4151
- Fullført
- Hepatitis Queensland
-
Ipswich, Queensland, Australia
- Rekruttering
- West Moreton Hospital and Health Service
-
Ta kontakt med:
- Blake Ponting
-
Hovedetterforsker:
- Blake Ponting
-
Rathdowney, Queensland, Australia, 4287
- Har ikke rekruttert ennå
- Palen Creek Correctional Centre
-
Ta kontakt med:
- Mike Hurley
- Telefonnummer: (07) 5544 3700
- E-post: mike.hurley@corrections.qld.gov.au
-
Townsville, Queensland, Australia
- Rekruttering
- Townsville Correctional Centre
-
Ta kontakt med:
- John Morey
-
Hovedetterforsker:
- John Morey
-
Woodford, Queensland, Australia
- Rekruttering
- Woodford Correctional Centre
-
Ta kontakt med:
- Rajendra Prakash
-
Hovedetterforsker:
- Rajendra Prakash
-
-
South Australia
-
Hackney, South Australia, Australia, 5069
- Rekruttering
- Hepatitis SA
-
Ta kontakt med:
- Lisa Carter
- Telefonnummer: (08) 8362 8443
- E-post: lisa@hepatitissa.asn.au
-
Marden, South Australia, Australia, 5070
- Har ikke rekruttert ennå
- South Australian Prison Health Service
-
Ta kontakt med:
- Tom Turnbull
-
Hovedetterforsker:
- Tom Turnbull
-
Mount Gambier, South Australia, Australia, 5290
- Rekruttering
- Mount Gambier Priosn
-
Ta kontakt med:
- William Galloway
-
Hovedetterforsker:
- William Galloway
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- Aktiv, ikke rekrutterende
- St Vincent's Correctional Health Services
-
Melbourne, Victoria, Australia, 3000
- Rekruttering
- Medically Supervised Injecting Room
-
Ta kontakt med:
- Nathan Stam
-
Hovedetterforsker:
- Nathan Stam
-
Ravenhall, Victoria, Australia, 3023
- Rekruttering
- Dame Phyllis Frost Centre
-
Ta kontakt med:
- Katelyn Mannix
- Telefonnummer: 1300 492 202
- E-post: katelyn.mannix@wh.org.au
-
Ravenhall, Victoria, Australia, 3023
- Rekruttering
- Geo Healthcare - The Geo Group Australia Pty Ltd
-
Ta kontakt med:
- David Grace
-
Hovedetterforsker:
- David Grace
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Beskrivelse
Inclusion Criteria:
- ≥ 18 years of age.
- Received point-of-care HCV testing.
Exclusion Criteria:
- Nil
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing. |
Participants will be offered finger-stick point-of-care testing for HCV |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Tidsramme: 12 Weeks from enrolment
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing. |
12 Weeks from enrolment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of participants who accept point-of-care testing
Tidsramme: 2 years from recruitment commencement
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing. |
2 years from recruitment commencement
|
|
The prevalence of HCV infection amongst study participants tested
Tidsramme: 2 years from recruitment commencement
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested. |
2 years from recruitment commencement
|
|
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Tidsramme: 52 weeks
|
To evaluate the length of time participants take to initiate HCV treatment after diagnosis |
52 weeks
|
|
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Tidsramme: 52 weeks
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV (DAA) treatment
Tidsramme: 52 weeks
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment. |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR
Tidsramme: 12 weeks
|
To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12). |
12 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Tidsramme: 52 weeks
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VHCRP2104
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Request to share IPD will be considered by the protocol steering committee on individual basis
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .